Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-01-04
2011-01-04
Davis, Zinna N (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S146000
Reexamination Certificate
active
07863292
ABSTRACT:
The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.
REFERENCES:
patent: 3989704 (1976-11-01), Houlihan et al.
patent: 4036964 (1977-07-01), Buckle et al.
patent: 4260611 (1981-04-01), Bartmann et al.
patent: 4559403 (1985-12-01), Bruderer et al.
patent: 4584379 (1986-04-01), Wagner
patent: 4673682 (1987-06-01), Konz et al.
patent: 4822800 (1989-04-01), Faltico et al.
patent: 4952588 (1990-08-01), Glamkowski et al.
patent: 4966906 (1990-10-01), Glamkowski et al.
patent: 5620995 (1997-04-01), Weidmann et al.
patent: 5658933 (1997-08-01), Weidmann et al.
patent: 5719164 (1998-02-01), Weidmann et al.
patent: 6093730 (2000-07-01), Weidmann et al.
patent: 6319931 (2001-11-01), Kroemer et al.
patent: 6358973 (2002-03-01), Napoletano et al.
patent: 6358976 (2002-03-01), Wityak et al.
patent: 6369053 (2002-04-01), Yuan et al.
patent: 6762318 (2004-07-01), Kodra et al.
patent: 6777425 (2004-08-01), Burli et al.
patent: 6903114 (2005-06-01), Backstrom et al.
patent: 7323475 (2008-01-01), Arend et al.
patent: 2003/0153503 (2003-08-01), Klaus et al.
patent: 2003/0176317 (2003-09-01), Guenzler-Pukall et al.
patent: 2004/0204356 (2004-10-01), Guenzler-Pukall et al.
patent: 2004/0235082 (2004-11-01), Fourney et al.
patent: 2005/0020487 (2005-01-01), Klaus et al.
patent: 2005/0171148 (2005-08-01), Mjalli et al.
patent: 2006/0178316 (2006-08-01), Klaus et al.
patent: 2006/0178317 (2006-08-01), Klaus et al.
patent: 2006/0183695 (2006-08-01), Klaus et al.
patent: 2006/0199836 (2006-09-01), Turtle et al.
patent: 2006/0251638 (2006-11-01), Guenzler-Pukall et al.
patent: 2006/0258660 (2006-11-01), Guenzler-Pukall et al.
patent: 2006/0258702 (2006-11-01), Guenzler-Pukall et al.
patent: 2006/0270699 (2006-11-01), Guenzler-Pukall et al.
patent: 2006/0276477 (2006-12-01), Klaus et al.
patent: 2007/0004627 (2007-01-01), Seeley et al.
patent: 2007/0155784 (2007-07-01), Arend et al.
patent: 2007/0185159 (2007-08-01), Arend et al.
patent: 2007/0292433 (2007-12-01), Seeley et al.
patent: 2007/0293575 (2007-12-01), Seeley et al.
patent: 2007/0298104 (2007-12-01), Arend et al.
patent: 2008/0004309 (2008-01-01), Deng et al.
patent: 2008/0293763 (2008-11-01), Arend et al.
patent: 2134866 (1995-05-01), None
patent: 0650960 (1994-10-01), None
patent: 0650961 (1994-10-01), None
patent: 0911340 (1999-04-01), None
patent: A-H07-224039 (1995-08-01), None
patent: A-H07-228571 (1995-08-01), None
patent: A-H11-302257 (1999-11-01), None
patent: WO 96/18616 (1996-06-01), None
patent: WO 01/58892 (2001-08-01), None
patent: WO 02/070510 (2002-09-01), None
patent: WO 02/100832 (2002-12-01), None
patent: WO 2002/101073 (2002-12-01), None
patent: WO 2003/053997 (2003-07-01), None
patent: WO 2004/052285 (2004-06-01), None
patent: WO 2004/108121 (2004-12-01), None
patent: WO 2004/108681 (2004-12-01), None
patent: WO 2005/007192 (2005-01-01), None
patent: WO 2005/009962 (2005-02-01), None
patent: WO 2005/011696 (2005-02-01), None
patent: WO 2005/014533 (2005-02-01), None
Duro et al, Farmaco, Edizione Scientifica (1981), 36(6), pp. 400-411.
Wu et al., Toxicology, 236, pp. 1-6, 2007.
English Translation of Duro et al, Farmaco, Edizione Scientifica (1981), 36(6), pp. 400-411.
Sato et al. “Stability and Physicochemical Properties of Viracept Tablets”Antibiotics and Chemotherapy14(9):1589-1592 (1998)—English Translation Not Available.
Ivan, et al. “HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O2 Sensing”,Science, 292:464-468.
Lando, et al. “Oxygen-dependent regulation of hypoxia-inducible factors by prolyl and asparaginyl hydroxylation”,Eur. J. Biochem, 270:781-790 (2003).
Richard, et al, “Nonhypoxic Pathway Mediates the Induction of Hypoxia-inducible Factor 1α in Vascular Smooth Muscle Cells”,J. Biol. Chm, 275:26765-26771 (2000).
Sandau, et al. “Induction of Hypoxia-Inducible-Factor 1 by Nitric Oxide Is Mediated via the P1 3K Pathway”Biochem. Biophys. Res. Commun., 278:263-267(2000).
Safran, et al. “HIF hydroxylation and the mammalian oxygen-sensing pathway”J. Clin. Invest. 111(6):779-783 (2003).
Sodhi, et al. “MAPK and Akt Act Cooperatively but independently on Hypoxia Inducible Factor-1α inrasV12 Unpregulation of VEGF”Biochem.Biophys. Res.Commun., 287:292-300 (2001).
Tacchini, et al. “Hepatocyte growth factor signaling stimulates hypoxia inducible factor-1 (HIF-1) activity in HepG2 hepatoma cells”Carcinogenesis, 22:1363-1371 (2001).
Franklin, et al., “Approaches to the Design of Anti-Fibrotic Drugs”, Biochem. Soc. Trans. 19(4): 812-815 (1991).
Jaakkola P, et al. (2001) Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292(5516):468-472.
Arend Michael P.
Du Xiaohui
Flippin Lee A.
Guenzler-Pukall Volkmar
Ho Wen-Bin
Davis Zinna N
Fibrogen Inc.
Foley & Lardner LLP
LandOfFree
Nitrogen-containing heteroaryl compounds and methods of use... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nitrogen-containing heteroaryl compounds and methods of use..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nitrogen-containing heteroaryl compounds and methods of use... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2725045